CLINICAL TRIALS PROFILE FOR HYDRALAZINE HYDROCHLORIDE; RESERPINE

All Clinical Trials for HYDRALAZINE HYDROCHLORIDE; RESERPINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000499 ↗	Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)	Completed	National Institute on Aging (NIA)	Phase 2	1980-09-01	The SHEP Pilot Study had six objectives, each designed to develop and test critical components of a full scale trial directed at the health consequences of treating isolated systolic hypertension (ISH) in the elderly. l. To estimate and compare the yield of participants for randomization into a clinical trial from various community groups using various recruitment techniques. 2. To estimate compliance with the visit schedule and to the prescribed double-blind regimens. 3. To estimate and compare the effectiveness of specified antihypertensive medications in reducing the blood pressure. 4. To estimate and compare the unwanted effects of specified antihypertensive medication in an elderly population. 5. To evaluate the feasibility and effectiveness of periodic behavioral assessment in this population. 6. To develop and test methods of ascertaining stroke and other disease endpoints.
NCT00000499 ↗	Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2	1980-09-01	The SHEP Pilot Study had six objectives, each designed to develop and test critical components of a full scale trial directed at the health consequences of treating isolated systolic hypertension (ISH) in the elderly. l. To estimate and compare the yield of participants for randomization into a clinical trial from various community groups using various recruitment techniques. 2. To estimate compliance with the visit schedule and to the prescribed double-blind regimens. 3. To estimate and compare the effectiveness of specified antihypertensive medications in reducing the blood pressure. 4. To estimate and compare the unwanted effects of specified antihypertensive medication in an elderly population. 5. To evaluate the feasibility and effectiveness of periodic behavioral assessment in this population. 6. To develop and test methods of ascertaining stroke and other disease endpoints.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.

Clinical Trial Conditions for HYDRALAZINE HYDROCHLORIDE; RESERPINE

Condition Name

Condition Name for HYDRALAZINE HYDROCHLORIDE; RESERPINE
Intervention	Trials
Hypertension	2
Cardiovascular Diseases	1
Heart Diseases	1
Vascular Diseases	1

Condition MeSH

Condition MeSH for HYDRALAZINE HYDROCHLORIDE; RESERPINE
Intervention	Trials
Hypertension	2
Vascular Diseases	1
Heart Diseases	1
Cardiovascular Diseases	1

Clinical Trial Locations for HYDRALAZINE HYDROCHLORIDE; RESERPINE

Trials by Country

Trials by Country for HYDRALAZINE HYDROCHLORIDE; RESERPINE
Location	Trials
United States	10
Puerto Rico	1

Trials by US State

Trials by US State for HYDRALAZINE HYDROCHLORIDE; RESERPINE
Location	Trials
Virginia	1
Tennessee	1
Pennsylvania	1
Ohio	1
Mississippi	1

Clinical Trial Progress for HYDRALAZINE HYDROCHLORIDE; RESERPINE

Clinical Trial Phase

Clinical Trial Phase for HYDRALAZINE HYDROCHLORIDE; RESERPINE
Clinical Trial Phase	Trials
Phase 2	1

Clinical Trial Status

Clinical Trial Status for HYDRALAZINE HYDROCHLORIDE; RESERPINE
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for HYDRALAZINE HYDROCHLORIDE; RESERPINE

Sponsor Name

Sponsor Name for HYDRALAZINE HYDROCHLORIDE; RESERPINE
Sponsor	Trials
VA Office of Research and Development	1
National Institute on Aging (NIA)	1
National Heart, Lung, and Blood Institute (NHLBI)	1

Sponsor Type

Sponsor Type for HYDRALAZINE HYDROCHLORIDE; RESERPINE
Sponsor	Trials
U.S. Fed	2
NIH	2

HYDRALAZINE HYDROCHLORIDE; RESERPINE Market Analysis and Financial Projection

Last updated: February 4, 2026

Clinical Trials Update for Hydralazine Hydrochloride and Reserpine

Hydralazine hydrochloride and reserpine are primarily used for hypertension management. Currently, no new clinical trial data has been posted publicly for either drug over the past 12 months, indicating no recent investigational activities or new indications. Existing trials are mostly related to ongoing assessment of efficacy and safety for established uses.

Market Analysis

Market Presence and Size

Hydralazine and reserpine are older antihypertensive agents. The global hypertension drug market was valued at approximately USD 24 billion in 2021. Hydralazine, a direct vasodilator, and reserpine, a centrally acting agent, occupy niche segments within this market.

Hydralazine maintains a presence in both patent and generic segments, with annual sales approximating USD 100 million in the U.S. as per IQVIA data. Reserpine, phased out of frontline therapy in many countries, mainly persists through generic sales, with global revenues under USD 50 million in 2022.

Market Dynamics

• Regulatory Environment: Limited recent updates; reserpine withdrew from some markets due to side effect profile, notably depression. Hydralazine remains approved for hypertension, hypertensive emergency, and heart failure.
• Competitive Landscape: Drugs like amlodipine, lisinopril, and hydrochlorothiazide dominate due to better safety profiles. Hydralazine and reserpine are often second-line or reserved for resistant hypertension.
• Pricing and Accessibility: Generic versions are widely available; pricing is stable but under pressure from newer agents offering improved tolerability.

Therapeutic and Market Trends

• Use of reserpine diminishes due to psychiatric side effects, replaced by agents with fewer Central Nervous System (CNS) adverse effects.
• Hydralazine's role remains mainly in hypertensive crises and heart failure, especially in resource-limited settings.

Projections

Future Growth

• Hydralazine: Expected to sustain a modest market presence, with a compound annual growth rate (CAGR) of approximately 2-3% over the next five years, driven by its utility in resistant hypertension and heart failure.
• Reserpine: Market decline expected to continue at a CAGR of -5% or more, as off-label and historical use diminishes and newer agents replace it.

Market Drivers and Risks

Drivers	Risks
Increasing hypertension prevalence globally	Negative side effect profiles impacting usage
Growing use in resistant and heart failure populations	Competition from newer, better-tolerated drugs
Preferential prescribing of combination therapies	Regulatory restrictions or withdrawal in certain markets

Regulatory Outlook

No significant regulatory initiatives have targeted these drugs for new indications or reformulation. The focus remains on old formulations with established safety profiles.

Key Takeaways

• No recent clinical trial activity for hydralazine hydrochloride or reserpine.
• The market size remains small relative to newer antihypertensives, with hydralazine maintaining a niche role.
• Hydralazine's sales are steady; reserpine's use continues to decline due to side effects.
• Future growth prospects rely on resistant hypertension and heart failure indications.

FAQs

1. Are there any ongoing clinical trials for hydralazine or reserpine?
No publicly registered clinical trials for either drug have been recorded in the last 12 months.

2. What are the main competitors to hydralazine?
Calcium channel blockers (amlodipine), ACE inhibitors (lisinopril), and diuretics (hydrochlorothiazide) primarily compete with hydralazine.

3. Why has reserpine declined in use?
Reserpine causes CNS side effects such as depression and sedation, leading to decreased prescribing in favor of agents with better tolerability.

4. Which markets hold the largest potential for hydralazine?
Resource-limited regions with high burdens of resistant hypertension and heart failure; China and India are notable.

5. What is the outlook for these drugs beyond hypertension?
Hydralazine has potential in heart failure with preserved ejection fraction (HFpEF); reserpine lacks further development prospects due to safety concerns.

References

1. IQVIA, "Global Prescription Audit," 2022.
2. MarketWatch, "Hypertension Drugs Market Size & Trends," 2021.
3. ClinicalTrials.gov, “Studies involving hydralazine or reserpine,” accessed March 2023.
4. FDA, "Drug Approvals and Label Changes," 2022.
5. WHO, "Global Hypertension Epidemiology," 2022.